Senator Orrin Hatch introduced a bill to allow easy research on medical marijuana. The bill titled ‘Marijuana Effective Drug Study Act of 2017’ or MEDS Act was introduced to the Congress in Washington D.C. If approved by the House, the Bill is expected to accelerate research on medical pot.
“It’s high time to address research into medical marijuana,” Hatch made a pun-filled statement in the House. “Our country has experimented with a variety of state solutions without properly delving into the weeds on the effectiveness, safety, dosing, administration, and quality of medical marijuana. All the while, the federal government strains to enforce regulations that sometimes do more harm than good,” Hatch said.
“To be blunt, we need to remove the administrative barriers preventing legitimate research into medical marijuana, which is why I’ve decided to roll out the MEDS Act.”
Senator Hatch was joined by Senator Schatz and cosponsors Senators Chris Coons, Senator Cory Gardner and Senator Thom Tillis.
“I urge my colleagues to join Senator Schatz and me in our joint effort to help thousands of Americans suffering from a wide-range of diseases and disorders. In a Washington at war with itself, I have high hopes that this bipartisan initiative can be a kumbaya moment for both parties,” he said.
While Senator Hatch stressed the importance of medical marijuana, he made it clear that he didn’t support the use of recreational pot.
The MEDS Act is expected to encourage research on the medical uses of marijuana by streamlining the research registration process and also make marijuana more available for legitimate scientific and medical research. Besides, the Bill focuses on codifying the administration’s decision to terminate the Public Health Service and its review of proposals for medical research on marijuana.